Omeros reported $200.57M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Adma Biologics USD 665.18M 40.94M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Immunic USD 189.74M 165.69M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.21B 56.38M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Rockwell Medical USD 52.62M 1.34M Jun/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xoma USD 263.15M 39.7M Sep/2025